Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2008

Open Access 01-12-2008 | Research article

A haplotype of polymorphisms in ASE-1, RAI and ERCC1and the effects of tobacco smoking and alcohol consumption on risk of colorectal cancer: a danish prospective case-cohort study

Authors: Rikke D Hansen, Mette Sørensen, Anne Tjønneland, Kim Overvad, Håkan Wallin, Ole Raaschou-Nielsen, Ulla Vogel

Published in: BMC Cancer | Issue 1/2008

Login to get access

Abstract

Background

Single nucleotide polymorphisms (SNPs) are the most frequent type of genetic variation in the human genome, and are of interest for the study of susceptibility to and protection from diseases. The haplotype at chromosome 19q13.2-3 encompassing the three SNPs ASE-1 G-21A, RAI IVS1 A4364G and ERCC1 Asn118Asn have been associated with risk of breast cancer and lung cancer. Haplotype carriers are defined as the homozygous carriers of RAI IVS1 A4364GA, ERCC1 Asn118AsnT and ASE-1 G-21AG. We aimed to evaluate whether the three polymorphisms and the haplotype are associated to risk of colorectal cancer, and investigated gene-environment associations between the polymorphisms and the haplotype and smoking status at enrolment, smoking duration, average smoking intensity and alcohol consumption, respectively, in relation to risk of colorectal cancer.

Methods

Associations between the three individual polymorphisms, the haplotype and risk of colorectal cancer were examined, as well as gene-environment interaction, in a Danish case-cohort study including 405 cases and a comparison group of 810 persons. Incidence rate ratio (IRR) were estimated by the Cox proportional hazards model stratified according to gender, and two-sided 95% confidence intervals (CI) and p-values were calculated based on robust estimates of the variance-covariance matrix and Wald's test of the Cox regression parameter.

Results

No consistent associations between the three individual polymorphisms, the haplotype and risk of colorectal cancer were found. No statistically significant interactions between the genotypes and the lifestyle exposures smoking or alcohol consumption were observed.

Conclusion

Our results suggest that the ASE-1 G-21A, RAI IVS1 A4364G and ERCC1 Asn118Asn polymorphisms and the previously identified haplotype are not associated with risk of colorectal cancer. We found no evidence of gene-environment interaction between the three polymorphisms and the haplotype and smoking intensity and alcohol consumption, respectively, in relation to the risk of colorectal cancer.
Appendix
Available only for authorised users
Literature
1.
Goode EL, Ulrich CM, Potter JD: Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev. 2002, 11: 1513-1530.PubMed
2.
Nexo BA, Vogel U, Olsen A, Ketelsen T, Bukowy Z, Thomsen BL, Wallin H, Overvad K, Tjonneland A: A specific haplotype of single nucleotide polymorphisms on chromosome 19q13.2-3 encompassing the gene RAI is indicative of post-menopausal breast cancer before age 55. Carcinogenesis. 2003, 24: 899-904. 10.1093/carcin/bgg043.CrossRefPubMed
3.
Vogel U, Laros I, Jacobsen NR, Thomsen BL, Bak H, Olsen A, Bukowy Z, Wallin H, Overvad K, Tjonneland A, Nexo BA, Raaschou-Nielsen O: Two regions in chromosome 19q13.2-3 are associated with risk of lung cancer. Mutat Res. 2004, 546: 65-74.CrossRefPubMed
4.
Vogel U, Sorensen M, Hansen RD, Tjonneland A, Overvad K, Wallin H, Nexo BA, Raaschou-Nielsen O: Gene-environment interactions between smoking and a haplotype of RAI, ASE-1 and ERCC1 polymorphisms among women in relation to risk of lung cancer in a population-based study. Cancer Lett. 2007, 247: 159-165. 10.1016/j.canlet.2006.04.001.CrossRefPubMed
5.
Skjelbred CF, Sabo M, Nexo BA, Wallin H, Hansteen IL, Vogel U, Kure EH: Effects of polymorphisms in ERCC1, ASE-1 and RAI on the risk of colorectal carcinomas and adenomas: A case control study. BMC Cancer. 2006, 6: 175-10.1186/1471-2407-6-175.CrossRefPubMedPubMedCentral
6.
Yang JP, Hori M, Sanda T, Okamoto T: Identification of a novel inhibitor of nuclear factor-kappaB, RelA-associated inhibitor. J Biol Chem. 1999, 274: 15662-15670. 10.1074/jbc.274.22.15662.CrossRefPubMed
7.
Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, Kagnoff MF, Karin M: IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell. 2004, 118: 285-296. 10.1016/j.cell.2004.07.013.CrossRefPubMed
8.
Chen X, Kandasamy K, Srivastava RK: Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling. Cancer Res. 2003, 63: 1059-1066.PubMed
9.
Laska MJ, Strandbygard D, Kjeldgaard A, Mains M, Corydon TJ, Memon AA, Sorensen BS, Vogel U, Jensen UB, Nexo BA: Expression of the RAI gene is conducive to apoptosis: studies of induction and interference. Exp Cell Res. 2007, 313: 2611-2621. 10.1016/j.yexcr.2007.05.006.CrossRefPubMed
10.
Yu HG, Yu LL, Yang Y, Luo HS, Yu JP, Meier JJ, Schrader H, Bastian A, Schmidt WE, Schmitz F: Increased expression of RelA/nuclear factor-kappa B protein correlates with colorectal tumorigenesis. Oncology. 2003, 65: 37-45. 10.1159/000071203.CrossRefPubMed
11.
Lind DS, Hochwald SN, Malaty J, Rekkas S, Hebig P, Mishra G, Moldawer LL, Copeland EM, Mackay S: Nuclear factor-kappa B is upregulated in colorectal cancer. Surgery. 2001, 130: 363-369. 10.1067/msy.2001.116672.CrossRefPubMed
12.
Saebo M, Skjelbred CF, Nexo BA, Wallin H, Hansteen IL, Vogel U, Kure EH: Increased mRNA expression levels of ERCC1, OGG1 and RAI in colorectal adenomas and carcinomas. BMC Cancer. 2006, 6: 208-10.1186/1471-2407-6-208.CrossRefPubMedPubMedCentral
13.
Bergamaschi D, Samuels Y, O'Neil NJ, Trigiante G, Crook T, Hsieh JK, O'Connor DJ, Zhong S, Campargue I, Tomlinson ML, Kuwabara PE, Lu X: iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human. Nat Genet. 2003, 33: 162-167. 10.1038/ng1070.CrossRefPubMed
14.
Rockenbauer E, Bendixen MH, Bukowy Z, Yin J, Jacobsen NR, Hedayati M, Vogel U, Grossman L, Bolund L, Nexo BA: Association of chromosome 19q13.2-3 haplotypes with basal cell carcinoma: tentative delineation of an involved region using data for single nucleotide polymorphisms in two cohorts. Carcinogenesis. 2002, 23: 1149-1153. 10.1093/carcin/23.7.1149.CrossRefPubMed
15.
Yin J, Rockenbauer E, Hedayati M, Jacobsen NR, Vogel U, Grossman L, Bolund L, Nexo BA: Multiple single nucleotide polymorphisms on human chromosome 19q13.2-3 associate with risk of Basal cell carcinoma. Cancer Epidemiol Biomarkers Prev. 2002, 11: 1449-1453.PubMed
16.
de Laat WL, Jaspers NG, Hoeijmakers JH: Molecular mechanism of nucleotide excision repair. Genes Dev. 1999, 13: 768-785. 10.1101/gad.13.7.768.CrossRefPubMed
17.
Viguier J, Boige V, Miquel C, Pocard M, Giraudeau B, Sabourin JC, Ducreux M, Sarasin A, Praz F: ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res. 2005, 11: 6212-6217. 10.1158/1078-0432.CCR-04-2216.CrossRefPubMed
18.
Park DJ, Zhang W, Stoehlmacher J, Tsao-Wei D, Groshen S, Gil J, Yun J, Sones E, Mallik N, Lenz HJ: ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy. Clin Adv Hematol Oncol. 2003, 1: 162-166.PubMed
19.
Ryu JS, Hong YC, Han HS, Lee JE, Kim S, Park YM, Kim YC, Hwang TS: Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer. 2004, 44: 311-316. 10.1016/j.lungcan.2003.11.019.CrossRefPubMed
20.
Zhou W, Gurubhagavatula S, Liu G, Park S, Neuberg DS, Wain JC, Lynch TJ, Su L, Christiani DC: Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res. 2004, 10: 4939-4943. 10.1158/1078-0432.CCR-04-0247.CrossRefPubMed
21.
Whitehead CM, Winkfein RJ, Fritzler MJ, Rattner JB: ASE-1: a novel protein of the fibrillar centres of the nucleolus and nucleolus organizer region of mitotic chromosomes. Chromosoma. 1997, 106: 493-502. 10.1007/s004120050271.CrossRefPubMed
22.
Schottenfeld D, Winawer SJ: Cancers of the large intestine. Cancer Epidemiology and Prevention. Edited by: Schottenfeld D and J.F.Jr. F. 1996, New York, Oxford University Press, 39: 813-840. second
23.
Hecht SS, Hoffmann D: Tobacco-specific nitrosamines, an important group of carcinogens in tobacco and tobacco smoke. Carcinogenesis. 1988, 9: 875-884. 10.1093/carcin/9.6.875.CrossRefPubMed
24.
Brooks PJ, Theruvathu JA: DNA adducts from acetaldehyde: implications for alcohol-related carcinogenesis. Alcohol. 2005, 35: 187-193. 10.1016/j.alcohol.2005.03.009.CrossRefPubMed
25.
Melikian AA, Sun P, Prokopczyk B, El-Bayoumy K, Hoffmann D, Wang X, Waggoner S: Identification of benzo[a]pyrene metabolites in cervical mucus and DNA adducts in cervical tissues in humans by gas chromatography-mass spectrometry. Cancer Lett. 1999, 146: 127-134. 10.1016/S0304-3835(99)00203-7.CrossRefPubMed
26.
Benhamou S, Laplanche A, Guillonneau B, Mejean A, Desgrandchamps F, Schrameck C, Degieux V, Perin F: DNA adducts in normal bladder tissue and bladder cancer risk. Mutagenesis. 2003, 18: 445-448. 10.1093/mutage/geg020.CrossRefPubMed
27.
Fang JL, Vaca CE: Detection of DNA adducts of acetaldehyde in peripheral white blood cells of alcohol abusers. Carcinogenesis. 1997, 18: 627-632. 10.1093/carcin/18.4.627.CrossRefPubMed
28.
Tjonneland A, Gronbaek M, Stripp C, Overvad K: Wine intake and diet in a random sample of 48763 Danish men and women. Am J Clin Nutr. 1999, 69: 49-54.PubMed
29.
Storm HH, Michelsen EV, Clemmensen IH, Pihl J: The Danish Cancer Registry--history, content, quality and use. Dan Med Bull. 1997, 44: 535-539.PubMed
30.
Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988, 16: 1215-10.1093/nar/16.3.1215.CrossRefPubMedPubMedCentral
31.
Laska MJ, Nexo BA, Vistisen K, Poulsen HE, Loft S, Vogel U: Polymorphisms in RAI and in genes of nucleotide and base excision repair are not associated with risk of testicular cancer. Cancer Lett. 2005, 225: 245-251. 10.1016/j.canlet.2005.03.021.CrossRefPubMed
32.
Barlow WE, Ichikawa L, Rosner D, Izumi S: Analysis of case-cohort designs. J Clin Epidemiol. 1999, 52: 1165-1172. 10.1016/S0895-4356(99)00102-X.CrossRefPubMed
33.
Barlow WE: Robust variance estimation for the case-cohort design. Biometrics. 1994, 50: 1064-1072. 10.2307/2533444.CrossRefPubMed
34.
Greenland S: Dose-response and trend analysis in epidemiology: alternatives to categorical analysis. Epidemiology. 1995, 6: 356-365.CrossRefPubMed
35.
Vogel U, Olsen A, Wallin H, Overvad K, Tjonneland A, Nexo BA: Effect of polymorphisms in XPD, RAI, ASE-1 and ERCC1 on the risk of basal cell carcinoma among Caucasians after age 50. Cancer Detect Prev. 2005, 29: 209-214. 10.1016/j.cdp.2005.01.001.CrossRefPubMed
36.
Gondal G, Grotmol T, Hofstad B, Bretthauer M, Eide TJ, Hoff G: Lifestyle-related risk factors and chemoprevention for colorectal neoplasia: experience from the large-scale NORCCAP screening trial. Eur J Cancer Prev. 2005, 14: 373-379. 10.1097/00008469-200508000-00010.CrossRefPubMed
Metadata
Title
A haplotype of polymorphisms in ASE-1, RAI and ERCC1and the effects of tobacco smoking and alcohol consumption on risk of colorectal cancer: a danish prospective case-cohort study
Authors
Rikke D Hansen
Mette Sørensen
Anne Tjønneland
Kim Overvad
Håkan Wallin
Ole Raaschou-Nielsen
Ulla Vogel
Publication date
01-12-2008
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2008
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-8-54

Other articles of this Issue 1/2008

BMC Cancer 1/2008 Go to the issue

Research article

Highly variable response to cytotoxic chemotherapy in carcinoma-associated fibroblasts (CAFs) from lung and breast

Research article

Epidermal growth factor receptor structural alterations in gastric cancer

Research article

Loss of heterozygosity at the ATBF1-A locus located in the 16q22 minimal region in breast cancer

Study protocol

ProsCan for Men: Randomised controlled trial of a decision support intervention for men with localised prostate cancer

Research article

The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer

Research article

Clinical implications of thymidylate synthetase, dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferase activity levels in colorectal carcinoma following radical resection and administration of adjuvant 5-FU chemotherapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits